All In Biotech

Drug Trial Radar · NCT04826107

Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer

An Open-label, Multicentre, Phase II Study of DP303c Injection in Patients With Unresectable Locally Advanced, Recurrent or Metastatic Gastric Cancer With HER2 Expression

Last checked: Nov 19, 2026Latest source record: Apr 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

196

Planned (sponsor's estimate)

Start

Aug 2021

Primary completion

Aug 2024

Study completion Dec 2024

Sponsor

Sponsor type
Industry
First posted
Apr 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter, phase II study to evaluate the efficacy and safety of DP303c injection in patients with HER2-positive advanced or metastatic gastric cancer.

Conditions

  • Gastric Cancer

Interventions

  • DP303c treatmentDrug

    DP303c injection, every 3 weeks.

  • DP303c treatment(second-line of HER2-positive)Drug

    DP303c injection, every 3 weeks.

  • DP303c treatment (third-line of HER2-positive)Drug

    DP303c injection, every 3 weeks.

  • DP303c treatment(≥second-line of HER2 low expressing)Drug

    DP303c injection, every 3 weeks.

  • DP303c + PD-1/PD-L1 treatmentDrug

    DP303c injection + PD-1/PD-L1 injection, dose and frequency to be determined.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR(Objective Response Rate)Time frame: Up to 2.5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.